Earnings ·
Liquidia Corporation reported second quarter 2026 financial results on August 12, 2026
LQDALiquidia Corp
Liquidia Corporation reported second quarter 2026 financial results on August 12, 2026. Net product sales for YUTREPIA reached approximately $170.4 million, a 31% increase from the first quarter of 2026. The company recorded net income of $74.7 million and adjusted EBITDA of $96.3 million, marking its fourth consecutive quarter of increasing profitability. Cash and cash equivalents totaled $284.2 million as of June 30, 2026. Since launching in June 2025, YUTREPIA has generated approximately 5,900 unique patient prescriptions and treated more than 5,000 patients. Liquidia Corporation is a biopharmaceutical company developing therapies for respiratory and vascular diseases using its proprietary PRINT technology.